CD274 and cancer: It has been proposed that cancer patient treatment with the PD-L1 mAb Avelumab might result in elimination of PD-L1+ cells by Antibody Dependent Cellular Cytotoxicity (ADCC), as suggested by in vitro data (30, 31); in contrast, the PD-L1 mAbs Atezolizumab and Durvalumab have an engineered Fc region to reduce ADCC (28, 29).